Moleculin Biotech (MBRX) today announced that 2-deoxy-D-glucose (“2-DG”) reduced the virus that causes COVID-19 by 100% in in vitro testing, according to independent research. On the news shares surged 155% in pre-market trading from $0.56 to $0.85.Researchers at the University of Frankfurt disclosed the findings in their article submitted to NatureResearch on March 11, 2020. The authors of the research reported that inhibiting glycolysis with non-toxic concentrations of 2-DG completely prevented SARS-CoV–2 replication in Caco–2 cells.Moleculin’s drug candidate, WP1122, is referred to as a “prodrug” of 2-DG as chemical elements are added to 2-DG to improve its delivery in vivo.“This is the breakthrough we were looking for, only it came from an unexpected source,” commented Walter Klemp, CEO of Moleculin. “Normally, we wouldn’t have access to data like this until it is published, but the willingness of the authors to pre-release this data will help support our development of WP1122 for treating...
Bitcoin Cash (BCH), one of bitcoin’s forks and the fourth-largest cryptocurrency by market capitalization, has just undergone its first halving at block number 630,000.The post Bitcoin Cash just went through its first halving appeared first on The Block....
